HALF-LIFE:Excretion of clascoterone has not been fully characterised in humans.
FDA APPROVAL DATE:08/26/2020
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH: No clinical studies evaluating the drug interaction potential of clascoterone (cream) have been conducted.
PREGNANCY: No available data to assess drug-associated risk of clascoterone in pregnant women.
Formulated as a cream with cetyl alcohol and other excipients. Local skin reactions (edema, erythema/redness, skin atrophy, stinging/burning, striae rubrea, telangiectasia) were observed during a treatment period with clascoterone cream, and occurred in a similar percentage of subjects treated with the vehicle cream.
Please login to view the rest of this drug profile.